Meeting
2017 Genitourinary Cancers Symposium
Population-based analysis of treatment toxicity among men with castration-resistant prostate cancer.
Authors
Robert Nam
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Robert Nam , Christopher J.D. Wallis , Refik Saskin , Symron Bansal , Urban Emmenegger , Raj Satkunasivam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Prostate Cancer,Urothelial Carcinoma,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 252)
DOI
10.1200/JCO.2017.35.6_suppl.252
Abstract #
252
Poster Bd #
C20
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).
First Author: Alexandra Sokolova
Poster
2020 Genitourinary Cancers Symposium
Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience.
First Author: Niamh Peters
Poster
2019 Genitourinary Cancers Symposium
Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
First Author: Alastair Thomson
Poster
2018 Genitourinary Cancers Symposium
AR-V7 in Asian patients with metastatic CRPC: A multinational, multicentre study.
First Author: Hui Shan Tan